Literature DB >> 17909539

Progress and prospects: gene therapy clinical trials (part 1).

B L Alexander, R R Ali, E W F Alton, J W Bainbridge, S Braun, S H Cheng, T R Flotte, H B Gaspar, M Grez, U Griesenbach, M G Kaplitt, M G Ott, R Seger, M Simons, A J Thrasher, A Z Thrasher, S Ylä-Herttuala.   

Abstract

Over the last two decades gene therapy has moved from preclinical to clinical studies for many diseases ranging from single gene disorders such as cystic fibrosis and Duchenne muscular dystrophy, to more complex diseases such as cancer and cardiovascular disorders. Gene therapy for severe combined immunodeficiency (SCID) is the most significant success story to date, but progress in many other areas has been significant. We asked 20 leaders in the field succinctly to summarize and comment on clinical gene therapy research in their respective areas of expertise and these are published in two parts in the Progress and Prospect series.

Entities:  

Mesh:

Year:  2007        PMID: 17909539     DOI: 10.1038/sj.gt.3303001

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

Review 1.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

2.  Gene delivery to the nervous system.

Authors:  Manfred Schubert; Xandra Breakefield; Howard Federoff; Robert M Frederickson; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2008-04       Impact factor: 11.454

Review 3.  Exosomes and their Application in Biomedical Field: Difficulties and Advantages.

Authors:  Jafar Rezaie; Saeed Ajezi; Çığır Biray Avci; Mohammad Karimipour; Mohammad Hossein Geranmayeh; Alireza Nourazarian; Emel Sokullu; Aysa Rezabakhsh; Reza Rahbarghazi
Journal:  Mol Neurobiol       Date:  2017-05-11       Impact factor: 5.590

Review 4.  Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.

Authors:  David A Williams; Adrian J Thrasher
Journal:  Stem Cells Transl Med       Date:  2014-03-28       Impact factor: 6.940

Review 5.  The retroviral vector family: something for everyone.

Authors:  Carina Elsner; Jens Bohne
Journal:  Virus Genes       Date:  2017-07-31       Impact factor: 2.332

6.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

7.  Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.

Authors:  William M Siders; Jacqueline Shields; Johanne Kaplan; Michael Lukason; Lisa Woodworth; Sam Wadsworth; Abraham Scaria
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

8.  Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro.

Authors:  Shan-zhi Gu; Xin-han Zhao; Ling-xiao Zhang; Li Li; Zhi-yu Wang; Min Meng; Gai-li An
Journal:  J Zhejiang Univ Sci B       Date:  2009-03       Impact factor: 3.066

9.  Design of hybrid lipid/retroviral-like particle gene delivery vectors.

Authors:  Rahul K Keswani; Ian M Pozdol; Daniel W Pack
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

Review 10.  Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.

Authors:  Anthony Scimè; Michael A Rudnicki
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.